Health Affairs · 2014 · 78 citations · 28 references
PharmacyOphthalmologyPharmacotherapyCost-effectiveness AnalysisPharmacoeconomic ModelingResource Utilization AnalysisCost-effectiveness ModelingMacular DegenerationMedicare AdvantagePharmacoeconomic EvaluationPrescription Drug CoverageRetinal PharmacotherapyDrug Budget Impact AnalysisDrug Cost AnalysisFuture Health BenefitsHealth Care Cost SavingsMedication Budget ImpactNeovascular Macular DegenerationPrescription Drug CostsPrescription Drug Spending
The biologic drugs bevacizumab and ranibizumab have revolutionized treatment of diabetic macular edema and neovascular age-related macular degeneration, leading causes of blindness. Ophthalmologic use of these drugs has increased and now accounts for roughly one-sixth of the Medicare Part B drug budget. The two drugs have similar efficacy and potentially minor differences in adverse-event rates; however, at $2,023 per dose, ranibizumab costs forty times more than bevacizumab. Using modeling methods, we predict ten-year (2010-20) population-level costs and health benefits of using bevacizumab and ranibizumab. Our results show that if all patients were treated with the less expensive bevacizumab instead of current usage patterns, savings would amount to $18 billion for Medicare Part B and nearly $5 billion for patients. With an additional $6 billion savings in other health care expenses, the total savings would be almost $29 billion. Altering patterns of use with these therapies by encouraging bevacizumab use and hastening approval of biosimilar therapies would dramatically reduce spending without substantially affecting patient outcomes.
28
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text
Medicine, Ophthalmology, Surgery +12
Prevalence of Age-related Maculopathy
Ronald Klein, Kathryn L.P. Linton · Ophthalmology · 1992 · 1.8K citations
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text
Ranibizumab for Diabetic Macular Edema
Quan Dong Nguyen, David M. Brown, Dennis M. Marcus et al. · Ophthalmology · 2012 · 1.6K citations
Medicine, Ophthalmology, Surgery +10